Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-230X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis ; volume:19 ; number:1 ; day:8 ; month:4 ; year:2019 ; pages:1-11 ; date:12.2019
BMC gastroenterology ; 19, Heft 1 (8.4.2019), 1-11, 12.2019
- Urheber
-
Pu, Ke
Wang, Yuping
Bai, Suyang
Wei, Hui
Zhou, Yongning
Fan, Jiangao
Qiao, Liang
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12876-019-0961-9
- URN
-
urn:nbn:de:101:1-2019042800100468758861
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pu, Ke
- Wang, Yuping
- Bai, Suyang
- Wei, Hui
- Zhou, Yongning
- Fan, Jiangao
- Qiao, Liang
- SpringerLink (Online service)
Ähnliche Objekte (12)
Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro
Comparative study of ultrasound attenuation analysis and controlled attenuation parameter in the diagnosis and grading of liver steatosis in non-alcoholic fatty liver disease patients
Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence
Controlled attenuation parameter-insulin resistance (CIR) score to predict non-alcoholic steatohepatitis
Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model
TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination
β-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats
The small GTPase RAB18: Insights into cellular steatosis, lipophagy and the non-alcoholic fatty liver disease
A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
The protective effects of Ninjin’yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse
Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease
Non-Invasive Separation of Alcoholic and Non-Alcoholic Liver Disease with Predictive Modeling
Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro
Comparative study of ultrasound attenuation analysis and controlled attenuation parameter in the diagnosis and grading of liver steatosis in non-alcoholic fatty liver disease patients
Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence
Controlled attenuation parameter-insulin resistance (CIR) score to predict non-alcoholic steatohepatitis
Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model
TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination
β-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats
The small GTPase RAB18: Insights into cellular steatosis, lipophagy and the non-alcoholic fatty liver disease
A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
The protective effects of Ninjin’yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse
Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease
Non-Invasive Separation of Alcoholic and Non-Alcoholic Liver Disease with Predictive Modeling
Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro
Comparative study of ultrasound attenuation analysis and controlled attenuation parameter in the diagnosis and grading of liver steatosis in non-alcoholic fatty liver disease patients
Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence
Controlled attenuation parameter-insulin resistance (CIR) score to predict non-alcoholic steatohepatitis
Decreased Hepatic Lactotransferrin Induces Hepatic Steatosis in Chronic Non-Alcoholic Fatty Liver Disease Model
TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination
β-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats
The small GTPase RAB18: Insights into cellular steatosis, lipophagy and the non-alcoholic fatty liver disease
A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
The protective effects of Ninjin’yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse
Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease